Roche Xenical Diabetes Data Could Provide Reimbursement Opportunity
Executive Summary
Roche Xenical four-year type II diabetes prevention data may help increase the number of patients who are reimbursed for the weight-loss drug
You may also be interested in...
Xenical OTC Switch Plans Underway; GSK Pays $100 Mil. For Rights
Roche and GlaxoSmithKline appear to be moving quickly on an Rx-to-OTC switch application for the anti-obesity agent Xenical (orlistat)
Xenical OTC Switch Plans Underway; GSK Pays $100 Mil. For Rights
Roche and GlaxoSmithKline appear to be moving quickly on an Rx-to-OTC switch application for the anti-obesity agent Xenical (orlistat)
Xenical Diabetes sNDA Withdrawn; FDA, Roche Disagree On Wording
Roche is contemplating how to pursue a type 2 diabetes indication for Xenical after withdrawing a supplemental NDA for the claim